内镜与非内镜手术治疗垂体腺瘤切除:一项全国数据库研究
基于美国国家癌症数据库2010至2016年确诊并接受手术的30,488例垂体腺瘤患者,比较内镜手术(ES)与非内镜手术(NES)。ES使用率随时间显著增加(OR 1.16,p<0.01),倾向评分匹配后ES组住院时间更短(3.9±4.9天 vs 4.3±5.4天,p<0.01),但全切除率、辅助放疗和90天死亡率无显著差异。
要点
- ES使用率逐年增加(OR 1.16,p<0.01),≥2 cm肿瘤中ES也呈时间性增加(OR 1.17,p<0.01)。
- 匹配后ES组住院时间更短(3.9±4.9天 vs 4.3±5.4天,p<0.01)。
- 全切除率(p=0.34)、辅助放疗(p=0.41)和90天死亡率(p=0.45)两组无显著差异。
核心结论
- 垂体腺瘤切除中内镜手术使用呈增加趋势,包括用于较大肿瘤。
- 内镜手术可能缩短住院时间,但全切除率、辅助治疗需求和短期死亡率可能相似。
- 肿瘤大小、保险状态、机构类型、收入、种族和合并症可能预测接受内镜手术。
研究设计与样本
- 查询美国国家癌症数据库,纳入2010至2016年组织学确诊、接受切除且手术入路明确的所有垂体腺瘤患者。
- 因数据库限制,显微手术和开颅手术均归为非内镜手术(NES)。
- 共识别30,488例患者,其中16,373例(53.7%)接受内镜手术(ES),14,115例(46.3%)接受NES。
主要发现
- ES使用随时间显著增加(OR 1.16,p<0.01),≥2 cm肿瘤中ES也呈时间性显著增加(OR 1.17,p<0.01)。
- 与NES相比,ES组患者更年轻(p=0.01)、更多在学术中心治疗(p<0.01)、居住地距治疗点更远(p<0.01)、肿瘤更小(p<0.01)、合并症负担更重(p=0.04)、有私人保险(p<0.01)、家庭收入更高(p<0.01)。
- 倾向评分匹配控制年龄、肿瘤大小、Charlson/Deyo评分和治疗中心类型后,ES组住院时间更短(3.9±4.9天 vs 4.3±5.4天,p<0.01),但全切除率(p=0.34)、辅助放疗(p=0.41)和90天死亡率(p=0.45)相似。
- 多因素logistic回归中,非裔美国人种族(OR 0.85,p<0.01)和肿瘤大小≥2 cm(OR 0.89,p=0.01)是接受ES的负性预测因素。
- 诊断年份较近(OR 1.16,p<0.01)、较高Charlson/Deyo评分(OR 1.10,p=0.01)、在学术机构治疗(OR 1.67,p<0.01)或治疗点距离≥20英里(OR 1.17,p<0.01)、有私人保险(OR 1.09,p=0.01)和较高家庭收入(OR 1.11,p=0.01)是接受ES的预测因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: For symptomatic nonsecreting pituitary adenomas (PAs), resection remains a critical option for treatment. In this study, the authors used a large-population national database to compare endoscopic surgery (ES) to nonendoscopic surgery (NES) for the surgical management of PA. METHODS: The National Cancer Database was queried for all patients diagnosed with histologically confirmed PA who underwent resection between 2010 and 2016 in which the surgical approach was specified. Due to database limitations, microsurgery and craniotomy were both categorized as NES. RESULTS: Of 30,488 identified patients, 16,373 (53.7%) underwent ES and 14,115 (46.3%) underwent NES. There was a significant increase in the use of ES over time (OR 1.16, p < 0.01). Furthermore, there was a significant temporal increase in ES approach for tumors ≥ 2 cm (OR 1.17, p < 0.01). Compared to NES, patients who underwent ES were younger (p = 0.01), were treated at academic centers (p < 0.01), lived a greater distance from their treatment site (p < 0.01), had smaller tumors (p < 0.01), had greater medical comorbidity burden (p = 0.04), had private insurance (p < 0.01), and had a higher household income (p < 0.01). After propensity score matching to control for age, tumor size, Charlson/Deyo score, and type of treatment center, patients who underwent ES had a shorter length of hospital stay (LOS) (3.9 ± 4.9 days vs 4.3 ± 5.4 days, p < 0.01), although rates of gross-total resection (GTR; p = 0.34), adjuvant radiotherapy (p = 0.41), and 90-day mortality (p = 0.45) were similar. On multivariate logistic regression, African American race (OR 0.85, p < 0.01) and tumor size ≥ 2 cm (OR 0.89, p = 0.01) were negative predictors of receiving ES, whereas diagnosis in more recent years (OR 1.16, p < 0.01), greater Charlson/Deyo score (OR 1.10, p = 0.01), receiving treatment at an academic institution (OR 1.67, p < 0.01) or at a treatment site ≥ 20 miles away (OR 1.17, p < 0.01), having private insurance (OR 1.09, p = 0.01), and having a higher household income (OR 1.11, p = 0.01) were predictive of receiving ES. Compared to the ES cohort, patients who started with ES and converted to NES (n = 293) had a higher ratio of nonwhite race (p < 0.01), uninsured insurance status (p < 0.01), longer LOS (p < 0.01), and higher rates of GTR (p = 0.04). CONCLUSIONS: There is an increasing trend toward ES for PA resection including its use for larger tumors. Although ES may result in shorter LOS compared to NES, rates of GTR, need for adjuvant therapy, and short-term mortality may be similar. Factors such as tumor size, insurance status, facility type, income, race, and existing comorbidities may predict receiving ES.
引用
- Goshtasbi K, Lehrich BM, Abouzari M, et al. Endoscopic versus nonendoscopic surgery for resection of pituitary adenomas: a national database study. J Neurosurg. 2020. PMID: 32168478. doi:10.3171/2020.1.JNS193062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。